ResMed Inc. (NYSE:RMD) insider James Hollingshead sold 600 shares of the stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $112.09, for a total transaction of $67,254.00. Following the sale, the insider now directly owns 83,689 shares of the company’s stock, valued at approximately $9,380,700.01. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
James Hollingshead also recently made the following trade(s):
- On Tuesday, November 27th, James Hollingshead sold 5,893 shares of ResMed stock. The shares were sold at an average price of $105.52, for a total transaction of $621,829.36.
- On Thursday, November 1st, James Hollingshead sold 600 shares of ResMed stock. The shares were sold at an average price of $105.93, for a total transaction of $63,558.00.
- On Monday, October 1st, James Hollingshead sold 600 shares of ResMed stock. The shares were sold at an average price of $115.88, for a total transaction of $69,528.00.
Shares of NYSE:RMD traded down $1.22 on Thursday, hitting $110.91. The company had a trading volume of 63,993 shares, compared to its average volume of 798,597. ResMed Inc. has a 1 year low of $83.60 and a 1 year high of $116.64. The company has a current ratio of 2.58, a quick ratio of 1.91 and a debt-to-equity ratio of 0.27. The stock has a market cap of $15.98 billion, a price-to-earnings ratio of 31.40, a P/E/G ratio of 2.86 and a beta of 1.01.
The business also recently announced a quarterly dividend, which will be paid on Thursday, December 13th. Stockholders of record on Thursday, November 8th will be given a $0.37 dividend. The ex-dividend date is Wednesday, November 7th. This represents a $1.48 annualized dividend and a dividend yield of 1.33%. ResMed’s dividend payout ratio is 41.93%.
Large investors have recently bought and sold shares of the company. Harvest Fund Management Co. Ltd lifted its position in shares of ResMed by 245.4% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 905 shares of the medical equipment provider’s stock worth $104,000 after purchasing an additional 643 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of ResMed by 144.7% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,018 shares of the medical equipment provider’s stock worth $117,000 after purchasing an additional 602 shares during the period. Qube Research & Technologies Ltd purchased a new stake in shares of ResMed in the 2nd quarter worth about $148,000. Cerebellum GP LLC purchased a new stake in shares of ResMed in the 3rd quarter worth about $186,000. Finally, Piedmont Investment Advisors LLC purchased a new stake in shares of ResMed in the 2nd quarter worth about $167,000. 65.02% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts have weighed in on the stock. BMO Capital Markets increased their price target on shares of ResMed from $107.00 to $109.00 and gave the company a “market perform” rating in a research report on Friday, October 26th. Credit Suisse Group raised shares of ResMed from a “neutral” rating to an “outperform” rating in a research report on Friday, October 26th. One analyst has rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $114.50.
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
Featured Article: What does EPS mean?
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.